Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy. - Trial NCT06218602
Access comprehensive clinical trial information for NCT06218602 through Pure Global AI's free database. This Phase 2 trial is sponsored by M.D. Anderson Cancer Center and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
M.D. Anderson Cancer Center
Timeline & Enrollment
Phase 2
Feb 19, 2024
Sep 10, 2026
Primary Outcome
Safety and adverse events (AEs)
Summary
To find out if adding treatment with fecal microbiota transplantation (FMT) is effective at
 treating gut-related side effects of antibiotic treatment in participants who are receiving
 standard therapy with anti-CD19 chimeric antigen receptor T-cell (CAR-T cell) therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06218602
Non-Device Trial